SHORT COMMUNICATION

COVID-19 Delta variants—Current status and implications as of August 2021

Flora Yu¹, Lok-Ting Lau², Manson Fok³, Johnson Yiu-Nam Lau²,* and Kang Zhang³,*

¹Department of Natural Sciences and Mathematics, University of Texas at Dallas, Richardson, Texas 75080-3021, USA
²Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR 999077, China
³University Hospital and Faculty of Medicine, Macau University of Science and Technology, Macau SAR 999078, China

*Correspondence: Kang Zhang, kang.zhang@gmail.com; Johnson Yiu-Nam Lau, johnsonynlau@aol.com

Abstract

The SARS-CoV-2 Delta variant has evolved as the dominant strain of the current pandemic. Studies have shown that this variant has increased infectivity/viral load, and reduced neutralization by the host antibodies from convalescent patients/vaccinees. Clinically, Delta variant infection has been observed/documented in convalescent patients/vaccinees, although with less incidence of severe diseases, but can serve as reservoir to spread the infection to the unvaccinated. The current understanding (as of 18 August 2021) on the virologic aspect (including the amino acid substitutions), clinical implications, and public health implications will be discussed in this mini review, and recommendations to health authorities will be provided.

Key words: SARS-CoV-2; COVID-19; coronavirus; Delta variant; transmissibility; vaccine

Introduction

Since its emergence in December 2019, COVID-19 has evolved into a pandemic.¹ As of 18 August 2021, there are >200 million people with confirmed infection globally (actual number likely much higher), contributing to >4 million deaths.²

SARS-CoV-2, closely related to the SARS-CoV, is a member of the genus Betacoronavirus.³,⁴ A positive-sense, single-stranded RNA virus of around 30,000 bases,⁵ it replicates using the viral RNA-dependent RNA polymerase, which lacks proof-reading activity. Therefore, the virus can easily generate genetic variations, allowing a genetically diverse population that can be selected through gained fitness and/or adaptation to the environment.⁶ Hence, rapid development of variants with increased infectivity and/or escape from the host immune response is to be expected, especially with a huge pool of infected subjects globally. Note that the genetic variations may or may not lead to amino acid substitutions/variations (known as synonymous and non-synonymous substitutions).⁷,⁸

Even with estimated genetic variation/mutation rate of one nucleotide substitution for every 10 replications, a single infected person, presumed to carry >10 billion...
copies of the virus, can produce billions of variations per day. When multiplied by the number of infected subjects globally, an enormous number of variants will be created. As the genetic scrambling is relatively random, most variants will have no impact. However, if the variant has increased infectivity/replication rate/genome stability, and/or can escape the host immune response, these variants can evolve as the dominant viral strain quickly.

The US government SARS-CoV-2 Interagency Group developed a Variant Classification that defines three types of variants: variant of interest (VOI), variant of concern (VOC), and variant of high consequences (VOHC). As of 18 August 2021, four VOCs have been reported (Table 1). The Alpha variant that initially emerged in UK has since spread to >185 countries. Studies have shown its increased transmission ability (50% increase), secondary infection attack rate, along with increased severity based on hospitalization rates. However, this variant has minimal impact on neutralization by convalescent and post-vaccination sera. The Beta strain was first described in South Africa, displaying both increased transmission and host antibody neutralization escape. The origin of the Gamma variant was traced to Japan/Brazil, and this variant has shown increased immune escape to neutralization antibodies.

The Delta strain, or B.1.617.2 variant of SARS-CoV-2, was first described in India in October 2020. By mid-2021, it had been detected in >142 countries. An additional spike amino acid change, K417N, was reported on 11 June (classified as the Delta Plus). As of 6 July 2021, this variant and another sub-lineage have been aggregated with the Delta variant. As of 17 August, >98% of the newly diagnosed COVID-19 cases in the USA result from the Delta variant. This mini review, with specific emphasis on the biology, clinical and public implications of the Delta variant, will provide the latest information related to the Delta variant as of 18 August 2021 to complement our previous review so that readers can have an update on the latest on COVID-19.

Amino acid substitutions in the Delta variant (B.1.617.2 variant)

COVID-19 gets its spike protein features from the coronavirus family. The spike proteins are flexible and hinge at three different points, thereby allowing easier access to the receptors on human cells. The receptor-binding domain (RBD) of the spike protein is the key binding element to the human angiotensin-converting enzyme 2 (hACE2) receptor. Two glycans play a key role in the positioning of the RBD and binding affinity to the hACE2 receptors, and there is evidence that the unique presence of the furin cleavage site found in SARS-CoV-2 is associated with its high infectivity in lungs.

There are a number of amino acid substitutions observed with the Delta variant, and the amino acid

| Variant | Date/Location | Spike protein amino acid substitutions | Enhanced binding to HACE2 | Furin cleavage | Transmission | Reinfeciton risk | Disease severity/hospitalization | Pfizer vaccine efficacy |
|---------|--------------|---------------------------------------|---------------------------|----------------|-------------|----------------|-------------------------------|-----------------------|
| Alpha   | September 2020, UK | 69–79del, 144del, E484K, S494P, N501Y, D614G, A570D, H655Y, T1027I |                           |               |           |                   |                               | 93.40%                |
| Beta    | September 2020, South Africa | D90A, D215G, 215del, E484K, N90S, K417N, L452R, E484Q, D614G, A701V |                           |               |           |                   |                               | 42% (infectious)      |
| Gamma   | December 2020, Japan/Brazil | D80A, D215F, 215del, N90I, D614G, G142D |                           |               |           |                   |                               | 42% (infectious)      |
| Delta   | October 2020, India | N501Y, D614G, T716I, S982A, D1119H, K1191N |                           |               |           |                   |                               | 42% (infectious)      |
| Delta Plus | October 2020, India | N501Y, D614G, T716I, S982A, D1119H, K1191N, L452R |                           |               |           |                   |                               | 42% (infectious)      |

N501Y, D614G is highlighted as a key amino acid substitution in the Delta variant. The amino acid mutations with (∗) indicate that the mutation of this particular amino acid may or may not occur, and will not affect a variant designation.
substitutions observed on the spike protein are summarized in Table 1. Some of the notable mutations found in the Delta variant such as D614G, L452R, E484Q, P681R, and T478K, can also be linked to other variants. Since the first description of the D614G mutation in China, this amino acid substitution has remained in all subsequent VOCs, with the main attribute being enhanced binding to hACE2 receptors. A key feature is L452R, which was discovered to enhance infectivity and decrease the neutralization ability of immune sera. Further studies also reported that L452R enhances membrane fusion, viral replication, and evades the HLA-A24 cell immunity. When L452R combined with E484Q, only a slight decrease in neutralization activity of immune sera was observed in vitro. The E484Q mutation has been observed to share similar immune neutralization escape properties with the E484K mutation in the Beta and Gamma variants. There were reports of reinfection being linked to the E484K mutation. As E484K and E484Q are close to each other, there is the concern regarding the reinfection potential of the Delta variant in convalescent patients and vaccinees. The P681R in the Delta variant is located near the furin cleavage site, similar to the P681H observed in the Alpha (UK) variant. Studies have shown that although P681R had decreased infectivity, it facilitates furin-mediated S cleavage, thereby enhancing viral fusion to ACE, promoting syncytia formation, and possibly facilitating immune escape.

T478K mutation is also found in the B.1.1.519 and B.1.214.3 lineages, located within the interaction domain of ACE2, and can possibly alter the electrostatic surface of the protein which greatly influences how treatments interact with the virus. An in vitro experiment suggested the mutation can escape immune recognition. An additional amino acid substitution K417N was also reported on 11 June 2021 with the new variant Delta Plus/AY.1. This variant has already spread to >30 countries by August 2021 and has been classified as a VOC in India.

Clinical implications

First identified in India, the Delta variant has evolved as the major viral strain in the current pandemic. Studies have shown that clinically, in addition to increased transmissibility, the variant has a shortened incubation time, enhanced replication abilities, and is more infectious compared to non-VOCs. A recent study reported that viral load is 1260 times higher in Delta variant patients than the original COVID-19 strain. In India, the major Delta variant-driven wave of infection started in March 2021 and started to recede by early July. In the UK where vaccination rate was high (76% adults), the Delta variant-driven surge started in July and had begun to recede by August. Overall, there was a 10% global increase in the number of infections and a 3% increase in deaths reported in the week of 13 July that were believed to relate mainly to the Delta variant surge (compared to the previous nine weeks with a steady decline in COVID-19 incidents).

In the US (with 50% of the population fully vaccinated), which had 8%–14% (7-day average of 13 500 COVID-19 cases/day) caused by the Delta variant in early June 2021, there was an increase to 80%–87% (7-day average of 92 000 COVID-19 cases/day) in the last two weeks of July. The Delta variant has evolved as the main driver for this pandemic in the US. Computer models have predicted that this surge may peak sometime in September and could increase the number of new infections significantly.

Public health implications

The observation that the Delta variant can infect vaccinees (therefore, can spread the infection) led CDC to change their recommendation that even fully vaccinated people should wear masks in indoor public places and in areas where transmission is high. The upcoming public health challenges will be when children are back at school, and when people move indoors during the coming fall and winter. We expect that there will soon be changes in public policy. Even before these challenges, the US has already seen a major wave of new infections coming, with several states reporting overloads of intensive care units.
Remdesivir is the first antiviral drug authorized for emergency use (EUA) by US FDA for the treatment of COVID-19. There are as yet no published data on the efficacy of remdesivir against the Delta variant. Currently, there are three sets of monoclonal antibodies against SARS-CoV-2 with EUAs: bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab. Bamlanivimab/etesevimab have been put on hold because of reduced efficacy against the Beta and Gamma strains, and the impact with the Delta variant is currently being studied.

A recent update on the effects of Pfizer mRNA 2 dose vaccination regime showed a reduction in hospital admissions (i.e. their efficacy endpoint) from 95% to 87.9%, while the prevalence of the Delta variant is increasing. As the host immune response is polyclonal against different B-cell/T-cell epitopes on the RBD based vaccine, it was not surprising that the vaccinees are still protected, and although some epitopes might be impacted by amino acid substitutions, exposure to vaccines enhances the host immune system and prevents development of severe COVID-19. Recently, there was an updated report that the Pfizer vaccine has 64% efficacy against infection and preventing symptomatic cases, but is 93% effective at preventing hospitalization/severe disease caused by the Delta variant. As of August 2021, another set of data showed that Moderna dropped from 86% to 76% efficacy against infection and Pfizer has dropped to 42%, while the Delta variant is evolving as the dominant strain. The Johnson and Johnson (JNJ) vaccine demonstrated 73.1% efficacy in preventing severe disease/hospitalization/death but no sub-analysis was performed for its efficacy against the Delta variant. Against the Beta variant, however, the efficacy of JNJ vaccine dropped to 52%.

Pfizer and BioNTech released a statement in early July 2021 that their booster trial showed neutralization titers 5 to 10 times higher against wild types and the Beta variant (no data on Delta variant yet) compared with their two-dose mRNA regime. An updated vaccine targeting the Delta variant and new regimens with booster shots to provide high levels of protection are currently projected to begin in August 2021.

As vaccinees may still have some level of protection against the Delta variant, with most vaccinees infected with Delta variant being asymptomatic/having mild diseases, and a vast majority of hospitalizations are unvaccinated individuals, the current COVID-19 pandemic has evolved to be a pandemic of the unvaccinated. Nasally administered vaccines are also in development, and it is possible that this may enhance local immune response to better protect the upper airways, which is where the body is first exposed to the virus. There are no approved inhalational vaccines yet, but in non-human primates, early humoral IgA immune responses has been shown to reduce viral shedding/transmission. It is also important to emphasize that these variants will sustain the current pandemic, and there will certainly be more long-term social/psychological/mental implications.

Conclusions

The SARS-CoV-2 Delta variant is a VOC and is currently the dominant strain in the prevailing COVID-19 pandemic. The high infectivity/viral load in infected subjects, and the enhanced susceptibility of the vaccinees to infection are concerning. Public health measures including continued use of face masks/social distancing in public areas should be considered by health authorities. Governments should strongly encourage all their citizens to be vaccinated. Clinics/hospitals should prepare for the new wave of infection caused by the Delta variant. Vaccines based on the Delta variant should be developed as soon as possible. The rapid evolution of SARS-CoV-2 variants suggests that we may see more SARS-CoV-2 variants of higher infectivity and/or reduced neutralizing activity of the convalescent/vaccinees in the future. A concerted effort to break the spread of the virus globally may be the only way to combat this pandemic.

Conflict of interests

The authors declare no competing financial interests. Besides, as a Co-EIC of Precision Clinical Medicine, the corresponding author Dr. Kang Zhang was blinded from reviewing or making decisions on this manuscript.

References

1. Wang H, Li X, Li T, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020;39:1629–35. doi:10.1007/s10096-020-03899-4.
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva (CH): World Health Organization; 2020 [cited 2021 Aug 11]. Available from: https://covid19.who.int/.
3. Nie J, Li Q, Zhang L, et al. Functional comparison of SARS-CoV-2 with closely related pangolin and bat coronaviruses. Cell Discov 2021;7:1–12. doi:10.1038/s41421-021-00256-3.
4. Pal M, Berhanu G, Desalegn C, et al. Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2): An update. Cureus 2020;12:e7423. doi:10.7759/cureus.7423.
5. Salleh MZ, Derrick JP, Deris ZZ. Structural evaluation of the spike glycoprotein variants on SARS-CoV-2 transmission and immune evasion. Int J Mol Sci 2021;22:7425. doi:10.3390/ijms22147425.
6. Payne S. Introduction to RNA viruses. Viruses 2017;97–105. doi:10.1016/B978-0-12-803109-4.00010-6.
7. Das JK, Roy S. A study on non-synonymous mutational patterns in structural proteins of SARS-CoV-2. Genome 2021;64(7):665–78. doi: 10.1159/gen-2020-0157.
8. Gene Mutation Detection Technology. Medical Trend; 2021 Mar 24 [cited 2021 Aug 11]. Available from: https://medicaltrend.org/2021/03/24/gene-mutation-detection-technology/.
9. Puiu T. All the SARS-CoV-2 viruses in the world weigh as little as an apple and as much as a small toddler. ZME Science 2021. Available from: https://www.zmescience.com/science/new-s-science/all-the-sars-cov-2-viruses-in-the-world-weigh-as-little-as-an-apple-and-as-much-as-a-small-toddler/.
10. Centers for Disease Control and Prevention (US). SARS-CoV-2 Variant Classifications and Definitions. Atlanta (GA): CDC. [Updated 2021 Aug 10]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/variants/variant-info.html.

11. World Health Organization. COVID-19 Weekly Epidemiological Update. Geneva (CH): World Health Organization; 2021 Aug 10 [cited 2021 Aug 11]; e52. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---10-august-2021.

12. Romano CM, Felix AC, de Paula AV, et al. SARS-CoV-2 reinfection caused by the P.1 lineage in Araraquara city, Sao Paulo State, Brazil. Rev Inst Med Trop Sao Paulo 2021;63:e36. doi:10.1590/S1678-9946202163036.

13. Ministry of Health and Family Welfare (IN). Delta and Delta Plus Variants: Frequently Asked Questions. New Delhi (IN). PIB Mumbai, 28 Jun. 2021. Available from: https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1730875.

14. Acharya B, Jamkhandikar S. Explainer: What is the Delta variant of coronavirus with K417 mutation? Pune (IN): Reuters; 2021 Jun 23 [cited 2021 Aug 11]. Available from: https://www.reuters.com/business/healthcare-pharma/ceuticals/what-is-delta-variant-coronavirus-with-k417-mutation-2021-06-23/.

15. Centers for Disease Control and Prevention (US). Division of Laboratory Systems (DLS). Lab Advisory: SARS-CoV-2 Variants AV.1 and AV.2 Now Aggregated with Delta Variant B.1.617.2. Atlanta (GA): CDC; 2021 July6. Available from: https://www.cdc.gov/cpse/dls/docs/07/2021/07-06-2021-lab-advisory-sars-cov-2-variants_av_1_and_av_2_now_aggregated_with_delta_variant_b_1_617_2.html.

16. Spencer SEW, Willey S. Delta variant spurring uptick in COVID-19 cases largely in unvaccinated. Worcester (MA): UMass Medical School; 2021 Jul 22 [cited 2021 Aug 11]. Available from: https://www.umassmed.edu/news/news-archives/2021/07/delta-variant-spurring-uptick-in-covid-19-cases-largely-in-unvaccinated/.

17. Mallucci L., McIntosh K., Tyrrell D. Virology. Coronaviruses. Nature 1968;220:650. doi:10.1038/220650b0.

18. Scudellari M. How the coronavirus infects cells — and why Delta is so dangerous. Nature 2021;595:640–4. doi:10.1038/d41586-021-02039-y.

19. Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 2021;595:273–5. doi:10.1038/s41586-021-03693-y.

20. Zhou Z, Du P, Yu M. Assessment of infectivity and the impact on neutralizing activity of immune sera of the COVID-19 variant, CAL.20C. Signal Transduct Target Ther 2021;6:285. doi:10.1038/s41392-021-00695-0.

21. Motozono C, Toyoda M, Zahradnik J, et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe 2021;29:1124–36.e11. doi:10.1016/j.chom.2021.06.006.

22. Li G, Zhou Z, Du P, et al. The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617.1 strain showed significant reduction in the neutralization activity of immune sera. Precis Clin Med 2021;4:149–54. doi:10.1093/pcmi/pba016.

23. Nonaka CKV, Franco MM, Gräf T, et al. Genomic evidence of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg Infect Dis 2021;27:1522–4. doi:10.3201/eid2705.210191.

24. Saito A, Irie T, Suzuki R, et al. SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion. BioRxiv 2021;4:16. doi:10.1101/2021.06.17.448820.

25. Di Giacomo S, Mercatelli D, Rakhimov A, et al. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol 2021;93:5638–43. doi:10.1002/jmv.27062.

26. Bendix A. The ‘Delta Plus’ variant has spread to nearly 30 countries, but low case numbers are a sign it won’t overtake Delta. Sunnyside (CA): Yahoo news; 2021 Aug 4 [cited 2021 Aug 12]. Available from: https://news.yahoo.com/delta-plus-variant-spread-nearly-231857146.html.

27. Reardon S. How the Delta variant achieves its ultra-fast spread. Nature 2021 Jul 21 [cited 2021 Aug 11]. doi:10.1038/d41586-021-01986-w.

28. McGregor G, Mukherji B, Mellor S. Delta waves in India and the U.K. have already receded. Could the same happen in the U.S.? NY (NY): Fortune; 2021 Aug 3 [cited 2021 Aug 11]. Available from: https://fortune.com/2021/08/03/covid-delta-variant-waves-uk-have-already-receded/.

29. The Visual and Data Journalism Team. Covid vaccine: How many people in the UK have been vaccinated so far? London (GB): BBC news; 2021 Aug 12 [cited 2021 Aug 12]. Available from: https://www.bbc.com/news/health-55274833.

30. World Health Organization. COVID-19 Weekly Epidemiological Update.Geneva (CH); WHO; 2021 Jul 13 [cited 2021 Aug 11]; ed.48. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021.

31. Wadman M. What does the Delta variant have in store for the United States? We asked coronavirus experts. Science Mag 2021 Aug 4 [cited 2021 Aug 11]. Available from: https://www.sciencemag.org/news/2021/08/what-does-delta-variant-have-store-us-we-asked-coronavirus-experts.

32. Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings — Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1059–62. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm?s_cid=mm7031e2_w#suggestedcitation. doi:10.15585/mmwr.mm7031e2.

33. Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci 2020;256:117900. doi:10.1016/j.lfs.2020.117900.

34. Chia PY, Ong SWX, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. MedRxiv 2021 [cited from 2021 Aug 11]. p.2021.07.28.21261295. doi:10.1101/2021.07.28.21261295.

35. Rasbach D. These are the symptoms of the COVID-19 delta variant.Bellingham (WA); The Bellingham Herald; 2021 Jul 8 [cited 2021 Aug 11]. Available from: https://www.msn.com/en-us/health/medical/these-are-the-symptoms-of-the-covid-19-delta-variant/ar-AALW016.

36. The Washington Post. Read: Internal CDC document on breakthrough infections. Washington (D.C): The Washington Post; 2021 Jul 30 [cited 2021 Aug 11]. Available from: https://www.washingtonpost.com/context/cdc-breakthrough-infections/94390e3a-5e45-44a5-ac40-2744e4e25f2e/?_t=1.

37. Centers For Disease Control and Prevention. Guidance For Fully Vaccinated People. Atlanta (GA): CDC; 2021 Jul 28. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated-guidance.html.

38. Fernandez M. CDC: Emerging evidence shows Delta variant may cause mild COVID among vaccinated people. Sunnyside
39. Linnane C. Austin, Texas is running out of ICU beds as U.S. daily average of COVID cases tops 100,000 to mark highest level since February. NY[NY]: Market Watch; 2021 Aug 9 [cited 2021 Aug 11]. Available from: https://www.msn.com/en-us/health/medical/austin-texas-is-running-out-of-icu-beds-as-us-daily-average-of-covid-cases-tops-100000-to-mark-highest-level-since-february/ar-AAN6V6x.

40. Bryant E. Final report confirms remdesivir benefits for COVID-19. Bethesda (MD): National Institute of Health; 2020 Oct 20. Available from: https://www.nih.gov/news-events/nih-research-matters/final-report-confirms-remdesivir-benefits-covid-19.

41. Gilead. Gilead’s Veklury (Remdesivir) associated with a reduction in mortality rate in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets. Foster City (CA): Gilead; 2021 Jun 21 [cited 2021 Aug 11]. Available from: https://www.gilead.com/news-and-press/press-releases/2021/6/gileads-veklury-remdesivir-associated-with-a-reduction-in-mortality-rate-in-hospitalized-patients-with-covid19-across-three-analyses-of-large-ret.

42. National Institute of Health. Anti-SARS-CoV-2 Monoclonal Antibodies. Bethesda (MD): National Institute of Health; [date unknown; updated 2021 Aug 4]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/.

43. Hasan A, Al-Ozairi E, Al-Baqumi Z, et al. Cellular and humoral immune responses in covid-19 and immunotherapeutic approaches. Immunotargets Ther 2021;10:63–85. doi:10.2147/ITT.S280706.

44. Linnane C. Israel says Pfizer vaccine just 64% effective in real world as delta variant continues to spread rapidly.NY[NY]: Market Watch; 2021 Jul 6 [cited 2021 Aug 6]. Available from: https://www.marketwatch.com/story/israel-says-pfizer-vaccine-just-64-effective-in-real-world-as-delta-variant-continues-to-spread-rapidly-11625582964.

45. Owens C. New data suggests Pfizer and Moderna’s vaccines may be less effective against Delta.Sunnydale (CA): Yahoo; 2021 Aug 11 [cited 2021 Aug 11]. Available from: https://news.yahoo.com/data-suggests-pfizer-modernas-vaccines-090012364.html.

46. Puranik A, Lenehan PJ, Silvert E, et al. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. medRxiv 2021. Aug 06 [cited 2021 Aug 11]. doi:10.1101/2021.08.06.21261707.

47. Sadoff J, Gray G, Vandeboesch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187–201. doi:10.1056/NEJMoa2101544.

48. Pfizer and BioNTech. Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant NY[NY] and Mainz (DE): Pfizer and BioNTech; 2021 Jul 8 [cited 2021 Jul 8]. Available from: https://cdn.pfizer.com/pfizercom/2021-07/Delta-Variant_Statement_Final_7.8.21.pdf?
xZjlwvaUMQ9sRnZFeKePcBirPFgw.

49. O’Donnell C, Mason J. Delta COVID variant now dominant strain worldwide, U.S. deaths surge -officials. London (GB): Reuters; 2021 Jul 16 [cited 2021 Aug 11]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/delta-covid-variant-now-dominant-worldwide-drive-surge-us-deaths-officials-2021-07-16/.

50. Tiboni M, Casettari L, Illum L. Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. Int J Pharm 2021;603:120686. doi:10.1016/j.ijpharm.2021.120686.

51. European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 5 August 2021. Stockholm (SE): European Centre for Disease Prevention and Control; [Updated 2021 Aug 5]. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern.

52. Liu Y, Liu J, Plante KS, et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. BioRxiv 2021 Mar 9 [cited 2021 Aug 13]. doi:10.1101/2021.03.08.101101.2021.03.08.434499.434499.

53. Frater F. The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study. BioRxiv 2020 Dec [cited 2021 Aug 13]. doi:10.1101/2020.12.23.424283.